Ultra‐long‐acting recombinant insulin for the treatment of diabetes mellitus in dogs

BACKGROUND: For the treatment of diabetes mellitus (DM) in dogs, novel insulins with decreased injection frequency while maintaining safety and efficacy are desirable. Insulin fused with immunoglobulin‐fragment‐crystallizable (Fc) has an ultra‐long plasma half‐life because it recycles through cells,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hulsebosch, Sean E., Pires, Jully, Bannasch, Michael J., Lancaster, Thomas, Delpero, Andrea, Ragupathy, Ramya, Murikipudi, Sylaja, Zion, Todd, Gilor, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
SMALL ANIMAL
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308417/
https://www.ncbi.nlm.nih.gov/pubmed/35621084
http://dx.doi.org/10.1111/jvim.16449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308417/
https://www.ncbi.nlm.nih.gov/pubmed/35621084
http://dx.doi.org/10.1111/jvim.16449

Ejemplares similares